The invention

Targeted therapy impairing oncogenic KRAS signalling by inhibition of KRAS–PDEDelta interaction

M: Medicine – Surgery – Orthopaedics – Material for disabled

Exhibition class: M: Medicine – Surgery – Orthopaedics – Material for disabled

Technical description: Anti-cancer drugs targeting PDEDelta, using RFdiffusion, ProteinMPNN, and Alphafold2 to generate peptides. ACP5 (KAPI) shows 80% inhibition in 2D cells and reduces Cisplatin doses, minimizing side effects in combination therapy.

Simplified description: Researchers are creating new anti-cancer drugs that focus on a protein called PDEDelta. They're using advanced tools to design peptides, which are short chains of amino acids, to fight cancer effectively. One promising peptide, called ACP5 (KAPI), can inhibit cancer cell growth by 80% in lab tests. Additionally, it helps lower the amount of chemotherapy drug Cisplatin needed, potentially reducing side effects for patients when used in combination therapy.